Biotage Receives its Largest Order to Date
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Biotage has announced that it has received its largest single order to date. It includes 31 instruments and totals approx. 15 MSEK.
The instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.
"It's encouraging that we have received an order of this magnitude so soon after the acquisition of Argonaut," says Jeff Bork, president and CEO of Biotage AB.
The instruments are designed to enable the scientists to simulate a number of processes under different conditions and to move from laboratory scale to production scale. The ordered instruments will be installed at the customer's plants in the US and Europe during 2005.
"We are seeing an increased interest worldwide in the pharmaceutical industry towards tools that reduce bottlenecks for process development and full-scale production," says David Patteson, president of Biotage, Discovery Chemistry Group.
He adds, "As Medicinal Chemistry accelerates the hit-to-lead process through automation, the emphasis now moves toward getting NCEs into clinical trials."
The instruments included in the order are Advantage Series® 2410 Personal Screening Synthesizers, Advantage Series® 3400 Multi-reactor Process Chemistry Workstations and Endeavor® Parallel Catalyst-screening Instruments.
The instruments, which originate from the recently acquired company Argonaut, will be used by chemists to enhance the processes used in the development of pharmaceuticals.
"It's encouraging that we have received an order of this magnitude so soon after the acquisition of Argonaut," says Jeff Bork, president and CEO of Biotage AB.
The instruments are designed to enable the scientists to simulate a number of processes under different conditions and to move from laboratory scale to production scale. The ordered instruments will be installed at the customer's plants in the US and Europe during 2005.
"We are seeing an increased interest worldwide in the pharmaceutical industry towards tools that reduce bottlenecks for process development and full-scale production," says David Patteson, president of Biotage, Discovery Chemistry Group.
He adds, "As Medicinal Chemistry accelerates the hit-to-lead process through automation, the emphasis now moves toward getting NCEs into clinical trials."
The instruments included in the order are Advantage Series® 2410 Personal Screening Synthesizers, Advantage Series® 3400 Multi-reactor Process Chemistry Workstations and Endeavor® Parallel Catalyst-screening Instruments.
